Imbalance Between Soluble and Membrane-Bound CD100 Regulates Monocytes Activity in Hepatitis B Virus-Associated

Dong-Na Zhang1, Ye Liu2, Xue Li1

  • 1Department of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China.

Viral Immunology
|March 1, 2021
PubMed

Insights

Hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) shows an imbalance in CD100, a key immune protein. This imbalance inactivates monocytes, potentially aiding patient survival.

Area of Science:

  • Immunology
  • Hepatology
  • Virology

Background:

  • CD100 is an immune semaphorin involved in infectious diseases.
  • Its role in hepatitis B virus (HBV)-associated acute-on-chronic liver failure (ACLF) and innate immunity regulation is unknown.

Purpose of the Study:

  • To investigate CD100 levels in HBV-ACLF patients.
  • To explore the modulatory function of CD100 on CD14+ monocytes in HBV-ACLF.

Main Methods:

  • Analyzed plasma-soluble CD100 (sCD100) and membrane-bound CD100 (mCD100) on CD14+ monocytes.
  • Assessed CD14+ monocyte cytotoxicity and T cell activation via co-culture systems with CD100 stimulation.

Main Results:

  • HBV-ACLF patients exhibited lower plasma sCD100 and higher mCD100 on CD14+ monocytes compared to controls.
  • CD14+ monocytes from HBV-ACLF patients showed reduced cytotoxicity and lower secretion of IFN-γ, TNF-α, and granzyme B.
  • Recombinant sCD100 enhanced monocyte cytotoxicity and T cell activation (CD4+ and CD8+) in HBV-ACLF patients.

Conclusions:

  • Severe inflammation in HBV-ACLF induces an sCD100/mCD100 imbalance.
  • This imbalance may lead to inactivated CD14+ monocyte responses, potentially contributing to patient survival.